Estrella Immunopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As of December 31, 2025 | As of December 31, 2024 | |
|---|---|---|
| Current Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,384,302 | $916,916 |
| Prepaid expenses and other receivable | 292,673 | 723,861 |
| Total current assets | 1,676,975 | 1,640,777 |
| Other Assets | ||
| Prepaid expenses, related party, non-current | 1,500,000 | 1,500,000 |
| Total Assets | $3,176,975 | $3,140,777 |
| Liabilities and Stockholders’ (Deficit) Equity | ||
| Current liabilities: | ||
| Accounts payable - related party | $554,781 | $4,435 |
| Other payables and accrued liabilities | 238,414 | 201,760 |
| Accrued liability - related party | 12,393,333 | 2,786,667 |
| Derivative liabilities | 356,505 | - |
| Franchise tax payable | - | 4,134 |
| Income tax payable | - | 50 |
| Total current liabilities | 13,543,033 | 2,997,046 |
| Total Liabilities | 13,543,033 | 2,997,046 |
| Commitments and Contingencies (Note 4) | ||
| Preferred Stock | ||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and 2024 | - | - |
| Stockholders’ (Deficit) Equity: | ||
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 38,486,219 and 36,680,870 shares issued as of December 31, 2025 and 2024, respectively | 3,849 | 3,668 |
| Additional paid-in capital | 27,219,287 | 24,636,283 |
| Accumulated deficit | (36,990,815) | (23,927,303) |
| Treasury stock, at cost 515,281 and 486,979 shares as of December 31, 2025 and 2024, respectively | (598,379) | (568,917) |
| Total Stockholders’ (Deficit) Equity | (10,366,058) | 143,731 |
| Total Liabilities and Stockholders’ (Deficit) Equity | $3,176,975 | $3,140,777 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.